Nativis, Inc., a clinical stage life sciences company, has entered into an evaluation agreement with a major pharmaceutical company based in Japan. The core purpose of the evaluation agreement is to confirm the results of both In-Vitro and In-Vivo experiments that have been successfully completed by Nativis at independent research facilities in the United States.
The pharmaceutical company will conduct additional experiments in its labs. Both companies also plan to continue discussions around other potential business opportunities involving Nativis technologies and products in Japan.
“We are very pleased to enter into this agreement,” stated Chris Rivera, Nativis chairman and chief executive officer. “We look forward to their findings and to our ongoing conversations about other potential collaborations.
Nativis is a clinical stage bioelectronics company, based in Seattle, Washington, that develops non-invasive treatments for cancers and other serious diseases.